Suppr超能文献

用于不可逆激酶抑制剂靶点鉴定的差异激酶珠分析

Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.

作者信息

Dittus Lars, Werner Thilo, Muelbaier Marcel, Bantscheff Marcus

机构信息

Cellzome GmbH, GlaxoSmithKline , Meyerhofstrasse 1, D-69117 Heidelberg, Germany.

出版信息

ACS Chem Biol. 2017 Oct 20;12(10):2515-2521. doi: 10.1021/acschembio.7b00617. Epub 2017 Sep 12.

Abstract

Chemoproteomics profiling of kinase inhibitors with kinobeads enables the assessment of inhibitor potency and selectivity for endogenously expressed protein kinases in cell lines and tissues. Using a small panel of targeted covalent inhibitors, we demonstrate the importance of measuring covalent target binding in live cells. We present a differential kinobeads profiling strategy for covalent kinase inhibitors where a compound is added either to live cells or to a cell extract that enables the comprehensive assessment of inhibitor selectivity for covalent and noncovalent targets. We found that Acalabrutinib, CC-292, and Ibrutinib potently and covalently bind TEC family kinases, but only Ibrutinib also potently binds to BLK. ZAK was identified as a submicromolar affinity Ibrutinib off-target due to covalent modification of Cys22. In contrast to Ibrutinib, 5Z-7-Oxozeaenol reacted with Cys150 next to the DFG loop, demonstrating an alternative route to covalent inactivation of this kinase, e.g., to inhibit canonical TGF-β dependent processes.

摘要

利用激酶磁珠对激酶抑制剂进行化学蛋白质组学分析,能够评估抑制剂对细胞系和组织中内源性表达的蛋白激酶的效力和选择性。通过使用一小部分靶向共价抑制剂,我们证明了在活细胞中测量共价靶点结合的重要性。我们提出了一种针对共价激酶抑制剂的差异激酶磁珠分析策略,即将化合物添加到活细胞或细胞提取物中,从而能够全面评估抑制剂对共价和非共价靶点的选择性。我们发现,阿卡替尼、CC - 292和伊布替尼能有效且共价结合TEC家族激酶,但只有伊布替尼也能有效结合BLK。由于半胱氨酸22的共价修饰,ZAK被鉴定为伊布替尼的亚微摩尔亲和力脱靶。与伊布替尼不同,5Z - 7 -氧代玉米烯醇与DFG环旁边的半胱氨酸150发生反应,证明了该激酶共价失活的另一条途径,例如抑制经典的转化生长因子 -β依赖性过程。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验